Results 81 to 90 of about 295,979 (212)

Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity

Health and Quality of Life Outcomes, 2019
Background/purpose The LFA REAL™ is a measurement system for evaluating lupus disease activity from both clinician and patient perspectives. Patients’ viewpoints are captured using a patient-reported outcome (PRO) questionnaire. A series of visual analog
Anca D. Askanase, R. Paola Daly, Miya Okado, Kayla Neville, Avery Pong, Leslie M. Hanrahan, Joan T. Merrill   +6 more
doaj   +1 more source

Irreversible blindness in juvenile systemic lupus erythematosus [PDF]

, 2011
Blindness caused by severe vasculitis or uveitis is rare in juvenile systemic lupus erythematosus (JSLE) patients. In a 27-year period, 5367 patients were followed at our Paediatric Rheumatology Division and 263 (4.9%) patients had JSLE (American College
AIKAWA, N. E., SILVA, C. A., SALLUM, A. M. E., JESUS, A. A., ALMEIDA, R. T., SA, L. C. F.   +5 more
core   +1 more source

THE TREATMENT OF LUPUS. [PDF]

The Lancet, 1903
n ...
openaire   +2 more sources

Spontaneous tendon rupture in systemic lupus erythematosus: association with Jaccoud`s arthropathy [PDF]

, 2010
Tendon rupture has rarely been described in patients with systemic lupus erythematosus. From observation of three cases of Jaccoud`s arthropathy with tendon rupture, and considering that this arthropathy is more related to an inflammatory process of the ...
MACIEIRA, J. C., CHIUCHETTA, F. A., ALVES, E. M., BORBA, E., SANTIAGO, M. B.   +4 more
core   +1 more source

On Lupus Carcinoma [PDF]

Annals of Surgery, 1888
n ...
openaire   +2 more sources

The UK Eastern Network for Kidney Inflammatory Disease (ENKID) MDT at 24 months: advancing access to high-cost drugs, clinical trials, and complex case management in renal autoimmune diseases

BMC Nephrology
Background Glomerulonephritis (GN) accounts for 20%–25% of the causes of chronic and end-stage kidney disease. The evolving treatment landscape with new targeted immunosuppressants has highlighted the unmet need for equity of access to specialist GN ...
Lucy Francis, Olivia Kanka, Ondrej Suchanek, Lisa C. Willcocks, Kevin W. Loudon, Clare Morlidge, Barbara Thompson, David C. Thomas, July Da Silva Araujo, Bernadette Laforteza, Praveen Jeevaratnam, Sapna Trivedi, Frances C. Hall, David R. W. Jayne, Rona M. Smith, Rachel B. Jones, On behalf of ENKID   +16 more
doaj   +1 more source

Lupus of the Epiglottis [PDF]

The American Journal of the Medical Sciences, 1903
n ...
openaire   +1 more source

National public health agenda for lupus 2015 : a blueprint for action [PDF]

The Agenda is organized and framed under the CDC Four Domains of Chronic Disease Prevention that include epidemiology and surveillance; environmental approaches; health care system interventions; and community programs linked to clinical services.

core  

LP-199 Medications given to patients with incomplete systemic lupus erythematosus

Lupus Science and Medicine, 2023
Anastasiia Shumilova, Yulia Gorbunova, Tatiana Popkova, Tatiana Panafidina, Liubov Kondrateva, Alexandr Lila   +5 more
doaj   +1 more source

Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report

Lupus Science and Medicine
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are currently lacking.
Tineke Kraaij, Cees van Kooten, Y K Onno Teng, Tom Huizinga, Eline J Arends, Robbert J Goekoop, Ton Rabelink, Mieke van Schaik, Marjolein J A L Wetzels, Stéphanie H Verbruggen, Sandra W van der Kooij, Sylvia W A Kamerling   +11 more
doaj   +1 more source